Aligos Progress and Fourth Quarter and Full Year 2024 Financial Results

 Positive

• Successful completion of $105M private placement financing
• 100% HBV DNA suppression achieved in Phase 1 trial for ALG-000184
• Reduced R&D expenses to $16.0M in Q4 2024 from $22.3M in Q4 2023
• Decreased G&A expenses to $5.2M from $6.4M year-over-year

Negative

• Net loss increased to $82.2M in Q4 2024 from $27.9M in Q4 2023
• Significant $60.8M loss from change in fair value of common warrants
• Cash position declined to $56.9M from $135.7M year-over-year

Insights

The planned advancement to Phase 2 by mid-2025 represents a significant milestone, particularly as management positions this compound as potentially first- and best-in-class with backbone therapy potential. The drug's mechanism as a capsid assembly modulator (CAM-E) targets a fundamental viral replication process, potentially offering advantages over current standard of care.

For their MASH program, ALG-055009 demonstrated placebo-adjusted median relative liver fat reductions up to 46.2% in Phase 2a, meeting its primary endpoint. The efficacy observed even in patients already on GLP-1 agonist therapy is strategically significant, suggesting potential complementary use alongside these increasingly popular agents. The additional cardiometabolic benefits, including reductions in atherogenic lipids like lipoprotein(a), enhance the compound's profile.

While management indicated they're exploring out-licensing options for the MASH program, this reflects appropriate resource allocation rather than doubting the asset's potential. Overall, the clinical data across multiple programs demonstrates meaningful scientific progress with potential therapeutic value.

The headline Q4 net loss of $82.2 million (versus $27.9 million in Q4 2023) requires context - the increase was primarily driven by a $60.8 million non-cash loss from change in warrant valuation rather than operational spending. Excluding this accounting adjustment, the operational performance showed improved efficiency with both R&D and G&A expenses decreasing year-over-year.

R&D expenses decreased to $16.0 million in Q4 2024 from $22.3 million in Q4 2023, while full-year R&D expenses fell slightly to $70.3 million from $73.0 million. Similarly, G&A expenses decreased to $5.2 million from $6.4 million for the quarter and to $22.8 million from $30.6 million for the full year. These reductions demonstrate improved operational efficiency while still advancing multiple clinical programs.

The company's strategy of seeking external funding for their coronavirus program while potentially out-licensing their MASH candidate shows disciplined capital allocation, allowing them to concentrate resources on their lead hepatitis B program. With sufficient capital secured and promising clinical data, Aligos is well-positioned to execute on their development plans through multiple value-creating milestones.

https://www.stocktitan.net/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-fourth-97jkh6ngu857.html